Should You Buy Ladbrokes PLC Instead Of AstraZeneca plc & International Consolidated Airlins Grp SA?

Could Ladbrokes PLC (LON: LAD) outperform the likes of AstraZeneca plc (LON: AZN) and International Consolidated Airlins Grp SA (LON: IAG)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Shares in betting firm Ladbrokes (LSE: LAD) have fallen by just 0.5% today despite the company reporting a hugely disappointing set of first half results. In fact, it has swung from a pretax profit in the first half of 2014 to a pretax loss in the first half of 2015, with shop closures and impairments contributing to a £51m pretax loss in the six months to June 30.

Clearly, this is hugely disappointing for the company’s investors and, while Ladbrokes has been touted as a strong dividend play owing to its relatively high yield, dividends have understandably been slashed. The company will now pay out 1p per share in its interim dividend, which is well down on the 4.3p per share that was paid in the first six months of last year.

Of course, the gaming industry is enduring a highly challenging period, with competition being very high and margins being squeezed. As such, sector consolidation is inevitable and Ladbrokes’ planned merger with Coral seems to make a lot of sense due to potential synergies and efficiencies that can be made. However, the road to recovery will be a challenging one and, while shares in Ladbrokes have already fallen by 16% in the last year, there could be further falls to come. As such, now does not appear to be the right time to buy a slice of the company.

However, there are a number of stunning investment opportunities within the FTSE 350. Notably, pharmaceutical company AstraZeneca (LSE: AZN) appears to offer a very bright future of growth and, while it has endured a difficult period in recent years as a result of the loss of patents, it is expected to begin delivering growth in the next few years.

Undoubtedly, AstraZeneca is not yet the finished product, with further acquisitions required in order to improve its pipeline. However, the strategy being adopted by the business is very sound and has seen AstraZeneca focus on treatments for health issues such as diabetes, which are expected to become major global challenges in the long run. Therefore, it is positioning itself for excellent long term growth and, even though a bid approach is less likely following the closing of a US tax loophole, its yield of 4.1% and price to earnings (P/E) ratio of 15.9 continue to indicate that it is a very strong buy.

Similarly, IAG (LSE: IAG), owner of British Airways, has also struggled to post strong financial numbers in recent years. For example, it made a loss in 2012 but, with an improving global economy and lower oil price positively impacting sales and costs respectively, its profitability is on the rise. For example, IAG is forecast to increase its bottom line by 75% this year and by a further 20% next year. This could improve investor sentiment moving forward and, even though IAG has posted a share price rise of 67% in the last year, its price to earnings growth (PEG) ratio of just 0.2 indicates that there could be further growth to come.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »